Dyne Therapeutics shares jump ahead of clinical data review

Investing.com — Dyne Therapeutics, a biotechnology company, saw its shares rise by up to 10% after the market closed on Wednesday.

The surge in stock price came as the company announced an investor conference call to review new clinical data.

The data is from its ACHIEVE trial, a study focusing on a yet undisclosed treatment. The company has not provided further details on the nature of the trial or the data to be reviewed.

Dyne Therapeutics, which specializes in developing therapies for patients with serious muscle diseases, said the review of the data is scheduled for January 10.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.